SV2016005236A - Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina - Google Patents

Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina

Info

Publication number
SV2016005236A
SV2016005236A SV2016005236A SV2016005236A SV2016005236A SV 2016005236 A SV2016005236 A SV 2016005236A SV 2016005236 A SV2016005236 A SV 2016005236A SV 2016005236 A SV2016005236 A SV 2016005236A SV 2016005236 A SV2016005236 A SV 2016005236A
Authority
SV
El Salvador
Prior art keywords
rosuvastatin
composite formulation
oral administration
ezetimibe
administration including
Prior art date
Application number
SV2016005236A
Other languages
English (en)
Inventor
Jae Hyun Park
Jung Hyun Cho
Jin Cheul Kim
Seung Jun Lee
Jong Soo Woo
Yong Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53791740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2016005236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SV2016005236A publication Critical patent/SV2016005236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PROPORCIONA UNA FORMULACIÓN COMPUESTA SÓLIDA PARA ADMINISTRACIÓN ORAL, INCLUYENDO LA FORMULACIÓN COMPUESTA SÓLIDA: UNA PARTE DE GRÁNULOS DE EZETIMIBE, QUE INCLUYE EZETIMIBE, TENIENDO DICHO EZETIMIBE UNA DISTRIBUCIÓN DE TAMAÑOS DE PARTÍCULAS EN LA QUE EL TAMAÑO MEDIO DE PARTÍCULAS D(0.9) PARA EL 90% INFERIOR ES ALREDEDOR DE 10 MICROM O MENOS; Y UNA PARTE DE MEZCLA DE ROSUVASTATINA, QUE INCLUYE ROSUVASTATINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y UN MÉTODO PARA PREPARAR LA FORMULACIÓN COMPUESTA
SV2016005236A 2013-12-30 2016-06-28 Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina SV2016005236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130167156 2013-12-30
KR1020140071081A KR20150079373A (ko) 2013-12-30 2014-06-11 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제

Publications (1)

Publication Number Publication Date
SV2016005236A true SV2016005236A (es) 2016-11-03

Family

ID=53791740

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005236A SV2016005236A (es) 2013-12-30 2016-06-28 Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina

Country Status (25)

Country Link
US (1) US10434067B2 (es)
EP (1) EP3089739A4 (es)
JP (1) JP2017500303A (es)
KR (2) KR20150079373A (es)
CN (1) CN105873571B (es)
AR (1) AR098996A1 (es)
AU (1) AU2014374552B2 (es)
CA (1) CA2933178A1 (es)
CL (1) CL2016001654A1 (es)
CR (1) CR20160293A (es)
DO (1) DOP2016000159A (es)
GT (1) GT201600137A (es)
MX (1) MX2016008725A (es)
MY (1) MY187637A (es)
NI (1) NI201600093A (es)
PE (1) PE20161072A1 (es)
PH (1) PH12016501196A1 (es)
RU (1) RU2683937C2 (es)
SG (1) SG10201805657PA (es)
SV (1) SV2016005236A (es)
TW (1) TWI655944B (es)
UA (1) UA117685C2 (es)
UY (1) UY35932A (es)
WO (1) WO2015102400A1 (es)
ZA (1) ZA201603934B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CZ2016539A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
KR101910902B1 (ko) * 2016-11-03 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR102206535B1 (ko) * 2016-11-29 2021-01-22 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
JP6848469B2 (ja) * 2017-01-20 2021-03-24 ニプロ株式会社 エゼチミブ含有医薬組成物の製造方法
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
KR102569271B1 (ko) * 2018-03-19 2023-08-23 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
GR1009727B (el) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
BR112022001783A2 (pt) 2019-07-31 2022-03-22 Tecnimede Sociedade Tecnico Medicinal Sa Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
MX2023002403A (es) * 2020-08-25 2023-03-22 Daewoong Pharmaceutical Co Ltd Composicion farmaceutica en forma de dosificacion individual para tratar o prevenir hipertension e hipercolesterolemia.
JP2022104836A (ja) * 2020-12-29 2022-07-11 日本ジェネリック株式会社 エゼチミブ及びロスバスタチンを含む錠剤
CN112999178A (zh) * 2021-03-01 2021-06-22 乐普制药科技有限公司 一种依折麦布匹伐他汀钙复方双层片剂
GB2622822A (en) * 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE59409631D1 (de) 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TR200402758T4 (tr) 2000-12-20 2004-11-22 Schering Corporation Hipokolesterolemik ajanlar olarak faydalı şekerle ikame edilen 2-azetidinonlar.
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
CA2457976A1 (en) 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
EP1648422A4 (en) 2003-07-28 2007-09-19 Reddys Lab Inc Dr TREATMENT AND PREVENTION OF CARDIOVASCULAR ACCIDENTS
MX2007012253A (es) 2005-04-04 2007-12-07 Univ Pontificia Catolica Chile Uso de ezetimibe para la prevencion y tratamiento de calculos de colesterol en la via biliar.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
CN101679236B (zh) * 2007-01-24 2013-03-06 克尔克公司 依泽替米贝的制备方法和其的衍生物
EP2120882A2 (en) * 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CA2725680A1 (en) * 2008-05-30 2009-12-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2008358622A1 (en) 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
ATE536172T1 (de) * 2009-03-13 2011-12-15 Sanovel Ilac Sanayi Ve Ticaret As Ezetimibzusammensetzungen
US20110196383A1 (en) 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
DK2844233T3 (da) 2012-05-01 2020-07-13 Althera Life Sciences Llc Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
EP2853263B1 (en) * 2012-05-22 2021-12-01 Kuhnil Pharm. Co. Ltd. Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
MX2012014970A (es) 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
KR20150079373A (ko) 2015-07-08
AU2014374552B2 (en) 2019-09-19
KR20150079454A (ko) 2015-07-08
PH12016501196B1 (en) 2016-08-15
UY35932A (es) 2015-07-31
AR098996A1 (es) 2016-06-22
US20160346213A1 (en) 2016-12-01
CR20160293A (es) 2016-10-05
RU2016123828A3 (es) 2018-08-28
CN105873571B (zh) 2019-10-22
ZA201603934B (en) 2017-09-27
RU2016123828A (ru) 2018-02-07
UA117685C2 (uk) 2018-09-10
US10434067B2 (en) 2019-10-08
NI201600093A (es) 2016-07-22
GT201600137A (es) 2018-10-19
MX2016008725A (es) 2017-02-28
CA2933178A1 (en) 2015-07-09
WO2015102400A1 (en) 2015-07-09
MY187637A (en) 2021-10-05
EP3089739A4 (en) 2017-08-02
TWI655944B (zh) 2019-04-11
SG10201805657PA (en) 2018-08-30
DOP2016000159A (es) 2016-12-15
RU2683937C2 (ru) 2019-04-03
TW201609091A (zh) 2016-03-16
CL2016001654A1 (es) 2017-01-06
PE20161072A1 (es) 2016-11-04
PH12016501196A1 (en) 2016-08-15
AU2014374552A1 (en) 2016-06-02
JP2017500303A (ja) 2017-01-05
EP3089739A1 (en) 2016-11-09
CN105873571A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
CY1123937T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201591821A1 (ru) Защищенные от несанкционированного использования фармацевтические составы
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JOP20150154B1 (ar) صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
NZ712341A (en) A crystalline form of an anxiolytic compound
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
GEP201706672B (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
MX2012013178A (es) Composicion antiparasitaria de amplio espectro de nitazoxanida, probioticos y prebioticos.
CL2019001424A1 (es) Comprimido compuesto oral que comprende ezetimiba y rosuvastatina.
MY198201A (en) A Combination Medicament Comprising Phenylephrine And Paracetamol
AR089764A1 (es) Composicion farmaceutica de administracion oral de nitazoxanida, util para el tratamiento de infecciones parasitarias intestinales, y proceso para preparar granulos para suspension de nitazoxanida
NZ712318A (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations